001     282565
005     20251202144730.0
024 7 _ |a 10.1038/s41582-025-01136-0
|2 doi
024 7 _ |a pmid:40983776
|2 pmid
024 7 _ |a 1759-4758
|2 ISSN
024 7 _ |a 1745-834X
|2 ISSN
024 7 _ |a 1745-8358
|2 ISSN
024 7 _ |a 1759-4766
|2 ISSN
037 _ _ |a DZNE-2025-01328
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Wirth, Thomas
|0 0000-0002-4427-5765
|b 0
245 _ _ |a Progress and challenges in sporadic late-onset cerebellar ataxias.
260 _ _ |a London
|c 2025
|b Macmillan Publishers Limited, part of Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1764683139_28227
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Sporadic late-onset cerebellar ataxia (SLOCA) is a syndrome defined by subacute or chronic and progressive ataxia occurring after the age of 40 years in individuals without a family history of ataxia. The 2022 publication of revised consensus diagnostic criteria for multiple system atrophy and the emergence of promising biomarkers provides a thorough diagnostic framework that now enables the diagnosis of numerous acquired causes of SLOCA, including autoimmune disorders and neurodegenerative diseases. The ongoing development and increased availability of DNA sequencing technology have uncovered several molecular causes of SLOCA besides spastic paraplegia type 7 and very late-onset Friedreich ataxia. These additional causes include sporadic genetic disorders, such as spinocerebellar atrophy type 27B, caused by GAA expansion in the FGF14 gene, and cerebellar ataxia with neuropathy and vestibular areflexia syndrome (CANVAS), caused by biallelic expansions in the RFC1 gene. This Review presents an updated clinical approach to the diagnosis and management of SLOCA that focuses on the most important developments in this field. Future challenges are also discussed, including the identification of additional missing genetic causes of SLOCA, especially via the use of long-read genome sequencing, improvements in SLOCA prognostication and the implementation of clinical trials of neuroprotective interventions.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Cerebellar Ataxia: diagnosis
|2 MeSH
650 _ 2 |a Cerebellar Ataxia: genetics
|2 MeSH
650 _ 2 |a Cerebellar Ataxia: therapy
|2 MeSH
650 _ 2 |a Age of Onset
|2 MeSH
700 1 _ |a Faber, Jennifer
|0 P:(DE-2719)2811327
|b 1
700 1 _ |a Depienne, Christel
|0 0000-0002-7212-9554
|b 2
700 1 _ |a Roze, Emmanuel
|b 3
700 1 _ |a Honnorat, Jérôme
|0 0000-0002-4721-5952
|b 4
700 1 _ |a Meissner, Wassilios G
|0 0000-0003-2172-7527
|b 5
700 1 _ |a Giunti, Paola
|b 6
700 1 _ |a Tranchant, Christine
|b 7
700 1 _ |a Klockgether, Thomas
|0 P:(DE-2719)2810314
|b 8
700 1 _ |a Anheim, Mathieu
|0 0000-0001-8121-0605
|b 9
773 _ _ |a 10.1038/s41582-025-01136-0
|g Vol. 21, no. 12, p. 687 - 705
|0 PERI:(DE-600)2491518-X
|n 12
|p 687 - 705
|t Nature reviews / Neurology
|v 21
|y 2025
|x 1759-4758
856 4 _ |u https://pub.dzne.de/record/282565/files/DZNE-2025-01328_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/282565/files/DZNE-2025-01328_Restricted.pdf?subformat=pdfa
|x pdfa
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2811327
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2810314
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2025-01-02
|w ger
915 _ _ |a DEAL Nature
|0 StatID:(DE-HGF)3003
|2 StatID
|d 2025-01-02
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-02
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-02
920 1 _ |0 I:(DE-2719)1011001
|k Clinical Research (Bonn)
|l Clinical Research Coordination
|x 0
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies (Bonn)
|l Patient Studies (Bonn)
|x 1
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1011001
980 _ _ |a I:(DE-2719)1011101
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21